Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
29 Cards in this Set
- Front
- Back
|
Causes of CHD
|
smokin , hypertension obesity, diabetes
|
|
|
wich patients should receive drugs ?
|
over 160 mg/dl LDL levels are candidates
|
|
|
statins are what inhibitors ?
|
HMG CoA reductase inhibitors
|
|
|
statins effect
|
lowers LDL , reduces CHD
|
|
|
First line treatment of elevated LDL
|
Statins
|
|
|
give 3 examples of statins
|
Pilavastatin, Rosuvastatin, Atorvastatin
|
|
|
Homozygous familial hypercholesterolemia
|
Lack LDL receptors
not benefit from statins |
|
|
Niacin can be used with
|
statins
|
|
|
Niacin increases
|
HDL levels
|
|
|
Most potent HDL increasing agent?
|
Niacin
|
|
|
Niacin inhibits?
|
LIPOLYSIS ,
results decreased plasma VLDL and LDL |
|
|
Niacin reduces LDL by %
|
10 - 20%
|
|
|
Adverse of Niacin ?
|
intense cutaneus flushing , itching skin
|
|
|
What decreases flsuhing of niacin?
|
take aspirin before
|
|
|
Niacin inhibits tubular ?
|
secretion of uric acid can lead to GOUT
|
|
|
What lowers serum triacylglycerol and increases HDL
|
Fenofibrate + Gemfibrozil
|
|
|
Fenofibrate + Gemfibrozil treats
|
Type 3 hyperlipidemia
|
|
|
in Type 3 hyperlipidemia what accumulates
|
IDL
|
|
|
adverse of Fenofibrate + Gemfibrozil
|
Gi-tract , Lithiasis, Myositis
elevate sulfonylureas not used in renal hepatic patients |
|
|
Fenofibrate and Gemfibrozil are derivates of
|
fibric acid
|
|
|
Bile acid binding resins
|
cholestyramine
colestipol colesevelam |
|
|
cholestyramine colestipol
colesevelam binds to |
negatively charged bile acids, bile salts
|
|
|
lowering bile acids concentration makes hepatocytes
|
convert cholesterol to bile acids
|
|
|
Bile acid binding are used in ?
|
type 2a and 2b hyperlipidemia
|
|
|
Bile acid resins advere effect
|
loss absorption of fat vitamins
|
|
|
cholesterol absorption inhibitors
|
Ezetimibe
|
|
|
Ezetimibe leads to
|
decreased delivery of intestinal cholesterol to liver
|
|
|
Ezetimibe decreases
|
LDL 17% triacylglycerol 6%
|
|
|
Ezetimibe not used in
|
Hepatic insuficiency
|
